Yohanis Irenius Mandik (Anggota tim Covid-19 UNCEN)
Abstract
Most drugs used in current medication for Covid-19 patient indicate several side effects due to the broad-spectrum drugs that affect the whole cells of human body (infected and healthy cells). Antiviral such as enzyme inhibitors, dideoxy, nucleoside/nucleotide analogs, amino acid analogs, even single chemical compound such as chloroquine phosphate, carboxylic acid type drugs and similar drugs may suppress some key molecules and changed pH not only in reactions which related to virus but also inevitably in the whole cells of human body. Based on all facts, then I designed the less cells destroying method to inhibit specifically SARS-CoV-2 replication in human cells. Since the sequence of single strand positive sense of SARS-CoV-2 has determined, the mechanism of its replication inside human lung cells was also well understood, the transport membrane (endocytosis) of oligonucleotides are well known and the supportive biotechnological methods are adequate to produce this type of drug then I proposed this methods and design respectively: 1) Study the specific sequence of SARS-CoV-2 RNA. 2) Synthesize the oligonucleotide using nucleotides analogs (to produce fake primers) that can specifically attach to the specific sequence of SARS-CoV-2 RNA. 3) Conduct in vitro experiments using the fake primers produced and the infected cells, study the efficiency of endocytosis of fake primers through cell membrane and to know the best dosage that can inhibit the SARS-CoV-2 replication. 4) Conduct clinical tests to the Covid-19 patients based on the in vitro test results (after passing the ethics protocol). So, the proposed novel narrow spectrum drug is the fake primer produced.
References
Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi
M, 2020. COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis. Journal of medical virology. doi: 10.1002/jmv.25719.
Artis Ventures, available from https://www.av.co/covid-treatments
Cascella M, Rajnik M, Cuomo A, et al. 2020.
Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Apr 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/.
Chan JF,Kok KH,Zhu Z,Chu H,To KK,Yuan S,Yuen KY, 2020. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes, 9(1):221-236.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM et al, 2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine. 382(13):1199-1207.
Perlman S, Netland J, 2009. Coronaviruses post-SARS: update on replication and pathogenesis. Nature reviews. Microbiology. 7(6):439-50.
Song W,Gui M,Wang X,Xiang Y, 2018. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS pathogens. 14(8):e10072
